Comparative Pharmacology
Head-to-head clinical analysis: CABAZITAXEL versus JEVTANA KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABAZITAXEL versus JEVTANA KIT.
CABAZITAXEL vs JEVTANA KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Microtubule inhibitor. Binds to tubulin and promotes microtubule assembly while inhibiting disassembly, leading to mitotic arrest and cell death. Also inhibits tubulin deacetylation and has anti-angiogenic properties.
JEVTANA KIT contains cabazitaxel, a microtubule inhibitor that promotes tubulin assembly and stabilizes microtubules, leading to G2/M cell cycle arrest and apoptosis.
25 mg/m2 intravenously every 3 weeks in combination with oral prednisone 10 mg daily.
60 mg/m² IV over 1 hour every 3 weeks in combination with oral prednisone 10 mg daily continuously.
None Documented
None Documented
Terminal half-life approximately 95 h (range 77–120 h) in patients with normal hepatic function; prolonged in hepatic impairment.
Clinical Note
moderateCabazitaxel + Verteporfin
"The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Verteporfin."
Clinical Note
moderateCabazitaxel + Digoxin
"Cabazitaxel may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCabazitaxel + Digitoxin
"Cabazitaxel may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCabazitaxel + Deslanoside
Terminal elimination half-life is approximately 95 hours (range 34–266 hours), supporting a prolonged dosing interval of every 3 weeks.
Primarily hepatobiliary (76% in feces as metabolites), renal (2-3% unchanged; 20% total in urine as metabolites).
Primarily biliary/fecal: ~75% of dose recovered in feces as unchanged drug and metabolites; renal excretion accounts for <5% of the dose.
Category C
Category C
Taxane Antineoplastic
Taxane Antineoplastic
"Cabazitaxel may decrease the cardiotoxic activities of Deslanoside."